Mutational Resistance Expected with Mass Indiscriminate Nirsevimab Injection of Infants
By Peter A. McCullough, MD, MPH The US FDA repeatedly pulled monoclonal antibodies against SARS-CoV-2 off the market because modeling studies demonstrated emerging mutational resistance. I wondered if the same challenges will exist for nirsevimab (Beyfortis, Sanofi, AstraZeneca) which have been injected in newborns on a mass indiscriminate basis since October, 2023 for the theoretical […]
Discuss on Nostr!
Nostr Note ID note1h2hzrfd3fngt6yslxgxgattrf8h9n53dr68z08s4nda4wpgwtt8qr6kn57 Open on Primal.net Open on Snort.social Open on Iris.to Open on Coracle.social
New to Nostr?
Create an account now & join the conversation!
Promote it on DissentWatch!
- To advertise this post for $0.02 per visit send bitcoins to the address below
- The post will be promoted daily via social media & our "Featured News" display in multiple places
- You can add more anytime
- Ranking order in the Featured News box is based on the balance remaining
Received: 0 mBTC (0.00 USD)
Spent: 0 mBTC (0.00 USD)
Balance: 0 mBTC (0.00 USD)
The amounts above may be lagging behind. If you just sent a payment click below to get more up to date results and push the post to the "Featured News" box faster.